Teva, Active Biotech halt higher doses of oral MS drug in trials

January 4, 2016 2:27 PM

24 0

JERUSALEM Jan 4 Teva Pharmaceutical Industries and Active Biotech will discontinue higher doses of their oral drug in development for multiple sclerosis in two trials, citing the occurrence of non-fatal cardiovascular events in eight patients.

Both trials of laquinimod will continue with the lower dose of 0.6 mg daily where there were no issues.

Read more

To category page

Loading...